Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Minimal residual disease in multiple myeloma
Prof Ola Landgren - University of Miami, Miami, USA
Minimal residual disease in multiple myeloma ( Prof Ola Landgren - University of Miami, Miami, USA )
8 Mar 2022
Lung cancer in India
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
3 Feb 2022
The Lancet Commission on women and cancer
Prof Richard Sullivan - Kings College London, London, UK & Prof Ophira Ginsburg ...
The Lancet Commission on women and cancer ( Prof Richard Sullivan - Kings College London, London, UK & Prof Ophira Ginsburg - International Agency for Research on Cancer, New York, USA )
3 Dec 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
22 Sep 2021
Anti-cancer drug price regulation in India: Financial implications and annual sa...
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Anti-cancer drug price regulation in India: Financial implications and annual savings to patients ( Dr Krishnamani Kalpathi  - American Oncology Institute, Hyderabad, India )
20 Sep 2021
Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative ch...
Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland
Neo-AEGIS: Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy ( Prof John Reynolds - Trinity College Dublin, Dublin, Republic of Ireland )
29 Jun 2021
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-r...
Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )
25 Jun 2021
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 ex...
Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
15 Jun 2021
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecula...
Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )
10 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Jun 2021
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA comp...
Dr Matthew Marx - Mirati Therapeutics, San Diego, USA
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )
30 Apr 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )
16 Apr 2021